A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy

David R H Christie, Natalia Mitina, Christopher F Sharpley, David R H Christie, Natalia Mitina, Christopher F Sharpley

Abstract

Introduction: Prostate-specific antigen (PSA) kinetic patterns during neoadjuvant androgen deprivation therapy have been shown to predict unfavorable long-term outcomes.

Objective: To investigate the effect of testosterone escape (TE) on these kinetic patterns, as this had not been previously reported.

Methods: There were 50 consecutive prostate cancer patients who received 6 months of triptorelin prior to definitive radiotherapy (RT). Testosterone and PSA levels were measured at baseline and every 6 weeks. Clinical factors were tested for their ability to predict for TE and unfavorable PSA kinetic patterns. The effects of TE, at both 1.7 and 0.7 nmol/L levels, were analyzed.

Results: TE occurred in at least one reading for 14% and 34% of the patients at the 1.7 and 0.7 nmol/L levels, respectively. No baseline factors predicted TE. The median PSA halving time was 25 days and the median pre-RT PSA level was 0.55 ng/mL. The only factor significantly associated with a higher pre-RT PSA level was a higher baseline PSA level. The only factor that significantly predicted a longer PSA halving time was TE at the 1.7 nmol/L level.

Conclusions: TE and higher baseline PSA levels may adversely affect PSA kinetics and other outcomes for patients undergoing neoadjuvant hormone therapy prior to radiotherapy. Studies investigating the tailoring of neoadjuvant therapy by extending the duration in those patients with a higher baseline PSA level or by the addition of anti-androgens in those demonstrating TE, should be considered.

Keywords: Gonadotropin-releasing hormone; Prostate-specific antigen; Prostatic neoplasm; Radiotherapy; Testosterone.

Conflict of interest statement

The authors declare that they have no financial conflict of interest with regard to the content of this report.

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Individual patient PSA levels (nmol/L).
Figure 2
Figure 2
Individual patient testosterone levels (ng/mL).

References

    1. Crawford DE, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 2018;22 (1):24–38.
    1. Pieczonka CM, Twardowski P, Renzulli J, et al. Effectiveness of subcutaneously administered leuprolide acetate to achieve low nadir testosterone in prostate cancer patients. Rev Urol 2018;20 (2):63–68.
    1. Nishiyama T. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the medical literature. Urol Oncol 2014;32 (1):38.e17–38.e28.
    1. Pickles T, Hamm J, Morris WJ, Schreiber WE, Tyldesley S. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? BJU Int 2012;110 (11 Pt B):E500–507.
    1. Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33 (10):1151–1156.
    1. Dason S, Allard CB, Tong J, Sheyagan B. Defining a new testosterone threshold for medical castration: results from a prospective cohort series. Can Urol Assoc J 2013;7 (5–6):e263–e267.
    1. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178 (4 Pt 1):1290–1295.
    1. Klotz L, Sheyagan B, Guillemette C, et al. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer—a Canadian consensus statement. Can Urol Assoc J 2018;12 (2):30–37.
    1. Zilli T, Dal Pra A, Kountouri M, Miralbel R. Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: a systematic review of the literature. Cancer Treat Rev 2016;46:35–41.
    1. Malik RM, Jani AB, Liauw SL. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;79 (4):1022–1028.
    1. Foo M, Lavieri M, Pickles T. Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database. Int J Radiat Oncol Biol Phys 2013;85 (2):385–392.
    1. Pinkawa M, Piroth MD, Holy R, et al. Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. Radiat Oncol 2012;7:209.
    1. Cuppone F, Bria E, Giannarelli D, et al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 2010;10:675.
    1. Heymann JJ, Benson MC, O’Toole KM, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate to high-risk localized prostate cancer. J Clin Oncol 2007;25 (1):77–84.
    1. Afriansyah A, Hamid AR, Mochtar CA, Umbas R. Prostate specific antigen (PSA) kinetics as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis. F1000Res 2018;7:246.
    1. Christie DRH, Sharpley CF. How accurately can prostate gland imaging measure the prostate gland volume? Results of a systematic review. Prostate Cancer 2019;2019:6932572.
    1. Bolton E, Lynch T. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. BJU Int 2018;122 (3):371–383.
    1. Wilke D, Patil N, Hollenhorst H, Bowes D, Rutledge R, Ago C. Testosterone suppression with luteinizing hormone-releasing hormone (LHRH) agonists in patients receiving radiotherapy for prostate cancer. Pharmacotherapy 2018;38 (3):327–333.
    1. Cerne JZ, McGuire SE, Grant SR, et al. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive therapy in prostate cancer patients. Prostate Cancer Prostatic Dis 2013;16 (4):346–351.
    1. Alexander AS, Mydin A, Jones SO, et al. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA) > 40 ng/ml: prognostic significance of the preradiation PSA nadir. Int J Radiat Oncol Biol Phys 2011;81 (5):e713–e719.
    1. Alexander A, Crook J, Jones S, et al. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2010;76 (1):23–30.
    1. McDonald AM, Jacob R, Yang ES, Dobelbower MC, Vanlandingham S, Fiveash JB. PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalation. Urol Oncol 2014;32 (5):687–693.
    1. Christie D, Windsor J, Sharpley. A systematic review of the accuracy of the digital rectal examination as a method of measuring the prostate gland volume. J Clin Urol 2019;12 (5):361–370.
    1. Morote J, Comas I, Planas J, et al. Serum testosterone levels in prostate cancer patients undergoing luteinizing hormone-releasing hormone agonist therapy. Clin Genitourin Cancer 2018;16 (2):e491–e496.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться